by David Kent | Jun 26, 2014
> The cellular therapy plenary at the ISSCR conference on June 19 was an incredibly interesting mix of hope and despair. On one hand, the opening talk by Leigh Turner made us imagine thousands of people in the United States getting duped into stem cell therapies as...
by Mark Curtis | Jun 25, 2014
. Welcome to your regenerative medicine deal review for the month of May. The space was quiet this past month; however, NeoStem did strike up a licensing deal with China-based Cellular Biomedicine Group to provide international reach to its newly acquired targeted...
by Lisa Willemse | Jun 3, 2014
> Bench to beside is a deceptively simple phrase. Only 15 characters and relatively jargon-free (assuming you know what bench and bedside are referring to), it’s rather easy to drop into documents or presentations without compromising space or time limits. And,...
by Nick Dragojlovic | May 26, 2014
> In a recent post on Signals, David Kent made the case for government-funded clinical trials of autologous stem cell therapies, since the lack of proven commercialization models in this area make it difficult to attract private investment. Another way of financing...
by Mark Curtis | May 22, 2014
. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...
Comments